Biotechnology
Compare Stocks
2 / 10Stock Comparison
TVGN vs BNTX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
TVGN vs BNTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.48B | $23.80B |
| Revenue (TTM) | $0.00 | $2.86B |
| Net Income (TTM) | $-31M | $-1.13B |
| Gross Margin | — | 77.7% |
| Operating Margin | — | -45.9% |
| Total Debt | $3M | $267M |
| Cash & Equiv. | $1M | $7.67B |
TVGN vs BNTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 22 | May 26 | Return |
|---|---|---|---|
| Tevogen Bio Holding… (TVGN) | 100 | 1.5 | -98.5% |
| BioNTech SE (BNTX) | 100 | 54.7 | -45.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TVGN vs BNTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TVGN is the clearest fit if your priority is growth exposure.
- EPS growth 47.6%
- -5.3% margin vs BNTX's -39.6%
BNTX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.05
- 5.8% 10Y total return vs TVGN's -98.5%
- Lower volatility, beta 1.05, Low D/E 1.4%, current ratio 7.54x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 0.2% revenue growth vs TVGN's -6.7% | |
| Quality / Margins | -5.3% margin vs BNTX's -39.6% | |
| Stability / Safety | Beta 1.05 vs TVGN's 1.95 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -0.7% vs TVGN's -86.3% | |
| Efficiency (ROA) | -5.3% ROA vs TVGN's -6.9% |
TVGN vs BNTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
TVGN vs BNTX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
TVGN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BNTX and TVGN operate at a comparable scale, with $2.9B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $2.9B |
| EBITDAEarnings before interest/tax | -$30M | -$931M |
| Net IncomeAfter-tax profit | -$31M | -$1.1B |
| Free Cash FlowCash after capex | -$13M | $277M |
| Gross MarginGross profit ÷ Revenue | — | +77.7% |
| Operating MarginEBIT ÷ Revenue | — | -45.9% |
| Net MarginNet income ÷ Revenue | — | -39.6% |
| FCF MarginFCF ÷ Revenue | — | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -24.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +13.5% | -2.1% |
Valuation Metrics
TVGN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.5B | $23.8B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $15.1B |
| Trailing P/EPrice ÷ TTM EPS | -79.91x | -17.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 7.36x |
| Price / BookPrice ÷ Book value/share | — | 1.01x |
| Price / FCFMarket cap ÷ FCF | — | 75.18x |
Profitability & Efficiency
BNTX leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -6.0% |
| ROA (TTM)Return on assets | -6.9% | -5.3% |
| ROICReturn on invested capital | — | -4.3% |
| ROCEReturn on capital employed | — | -3.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | — | 0.01x |
| Net DebtTotal debt minus cash | $2M | -$7.4B |
| Cash & Equiv.Liquid assets | $1M | $7.7B |
| Total DebtShort + long-term debt | $3M | $267M |
| Interest CoverageEBIT ÷ Interest expense | -219.56x | -62.15x |
Total Returns (Dividends Reinvested)
BNTX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BNTX five years ago would be worth $4,756 today (with dividends reinvested), compared to $151 for TVGN. Over the past 12 months, BNTX leads with a -0.7% total return vs TVGN's -86.3%. The 3-year compound annual growth rate (CAGR) favors BNTX at -4.5% vs TVGN's -76.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -58.9% | -2.7% |
| 1-Year ReturnPast 12 months | -86.3% | -0.7% |
| 3-Year ReturnCumulative with dividends | -98.6% | -12.9% |
| 5-Year ReturnCumulative with dividends | -98.5% | -52.4% |
| 10-Year ReturnCumulative with dividends | -98.5% | +575.8% |
| CAGR (3Y)Annualised 3-year return | -76.0% | -4.5% |
Risk & Volatility
BNTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BNTX is the less volatile stock with a 1.05 beta — it tends to amplify market swings less than TVGN's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BNTX currently trades 75.9% from its 52-week high vs TVGN's 9.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.95x | 1.05x |
| 52-Week HighHighest price in past year | $75.50 | $124.00 |
| 52-Week LowLowest price in past year | $0.35 | $79.52 |
| % of 52W HighCurrent price vs 52-week peak | +9.9% | +75.9% |
| RSI (14)Momentum oscillator 0–100 | 55.5 | 40.1 |
| Avg Volume (50D)Average daily shares traded | 34K | 1.2M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TVGN as "Hold" and BNTX as "Buy".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | — | $139.44 |
| # AnalystsCovering analysts | 1 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
BNTX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). TVGN leads in 2 (Income & Cash Flow, Valuation Metrics).
TVGN vs BNTX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is TVGN or BNTX a better buy right now?
Analysts rate BioNTech SE (BNTX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TVGN or BNTX?
Over the past 5 years, BioNTech SE (BNTX) delivered a total return of -52.
4%, compared to -98. 5% for Tevogen Bio Holdings Inc. (TVGN). Over 10 years, the gap is even starker: BNTX returned +575. 8% versus TVGN's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TVGN or BNTX?
By beta (market sensitivity over 5 years), BioNTech SE (BNTX) is the lower-risk stock at 1.
05β versus Tevogen Bio Holdings Inc. 's 1. 95β — meaning TVGN is approximately 85% more volatile than BNTX relative to the S&P 500.
04Which has better profit margins — TVGN or BNTX?
Tevogen Bio Holdings Inc.
(TVGN) is the more profitable company, earning 0. 0% net margin versus -39. 6% for BioNTech SE — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TVGN leads at 0. 0% versus -22. 6% for BNTX. At the gross margin level — before operating expenses — BNTX leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TVGN or BNTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TVGN or BNTX better for a retirement portfolio?
For long-horizon retirement investors, BioNTech SE (BNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
05), +575. 8% 10Y return). Tevogen Bio Holdings Inc. (TVGN) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BNTX: +575. 8%, TVGN: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TVGN and BNTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.